Literature DB >> 8957147

Randomised double-blind comparison of lofexidine and methadone in the in-patient treatment of opiate withdrawal.

J Bearn1, M Gossop, J Strang.   

Abstract

This study compares the clinical responses to methadone and lofexidine in the treatment of opiate withdrawal in 86 polydrug-abusing opiate addicts, using a randomised double-blind study design. The lofexidine treatment more severe symptoms from day 3 to 7 and again on day 10 (the last day of treatment), but thereafter both groups showed a similar progressive symptom decline. There was no significant difference in rates of treatment completion. Both treatments had similar effects on blood pressure. Lofexidine is broadly clinically equivalent to methadone, and appears to be a non-opiate treatment of opiate withdrawal without serious limiting hypotensive side effects.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957147     DOI: 10.1016/s0376-8716(96)01289-6

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  11 in total

1.  Evidence-based addiction medicine: the use of lofexidine for opioid detoxification.

Authors:  Babatunde Adetunji; Maju Mathews; Adedapo Williams; Olusanya Rufai
Journal:  Psychiatry (Edgmont)       Date:  2004-11

2.  Guanfacine enhances inhibitory control and attentional shifting in early abstinent cocaine-dependent individuals.

Authors:  Helen Fox; Mehmet Sofuoglu; Rajita Sinha
Journal:  J Psychopharmacol       Date:  2015-01-07       Impact factor: 4.153

Review 3.  Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?

Authors:  Timothy E Albertson; James Chenoweth; Jonathan Ford; Kelly Owen; Mark E Sutter
Journal:  J Med Toxicol       Date:  2014-12

Review 4.  The role of guanfacine as a therapeutic agent to address stress-related pathophysiology in cocaine-dependent individuals.

Authors:  Helen Fox; Rajita Sinha
Journal:  Adv Pharmacol       Date:  2014

Review 5.  Methadone at tapered doses for the management of opioid withdrawal.

Authors:  Laura Amato; Marina Davoli; Silvia Minozzi; Eliana Ferroni; Robert Ali; Marica Ferri
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

6.  Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.

Authors:  Margaret Haney; Carl L Hart; Suzanne K Vosburg; Sandra D Comer; Stephanie Collins Reed; Richard W Foltin
Journal:  Psychopharmacology (Berl)       Date:  2007-12-27       Impact factor: 4.530

7.  A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.

Authors:  Elmer Yu; Karen Miotto; Evaristo Akerele; Ann Montgomery; Ahmed Elkashef; Robert Walsh; Ivan Montoya; Marian W Fischman; Joseph Collins; Frances McSherry; Kathy Boardman; David K Davies; Charles P O'Brien; Walter Ling; Herbert Kleber; Barbara H Herman
Journal:  Drug Alcohol Depend       Date:  2008-05-27       Impact factor: 4.492

Review 8.  Alpha₂-adrenergic agonists for the management of opioid withdrawal.

Authors:  Linda Gowing; Michael Farrell; Robert Ali; Jason M White
Journal:  Cochrane Database Syst Rev       Date:  2016-05-03

9.  Comparison of the efficacy of buprenorphine and clonidine in detoxification of opioid-dependents.

Authors:  Hassan Ziaaddini; Mansooreh Nasirian; Nouzar Nakhaee
Journal:  Addict Health       Date:  2012 Summer-Autumn

Review 10.  Pharmacological therapies for management of opium withdrawal.

Authors:  Afarin Rahimi-Movaghar; Jaleh Gholami; Laura Amato; Leila Hoseinie; Reza Yousefi-Nooraie; Masoumeh Amin-Esmaeili
Journal:  Cochrane Database Syst Rev       Date:  2018-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.